Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharm...
Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, sh...
https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and...
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placeb...
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated ...
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 6...
